Ovarian removal and subsequent breast cancer prognosis: a nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Purpose: To evaluate whether previous ovarian removal concomitant with benign hysterectomy improves prognosis in a cohort of women with breast cancer. Methods: In this nationwide register-based cohort study, risk of recurrence and mortality were examined in 4563 women with invasive breast cancer and previous bilateral salpingo-oophorectomy (BSO) concomitant with benign hysterectomy, during 1977–2018. Comparing with benign hysterectomy alone, hazard ratios (HRs) and 95% confidence intervals (CIs) were evaluated by Cox-proportional hazards regression models. Analyses were stratified on age at hysterectomy as a proxy for menopausal status (< 45, 45–54 and ≥ 55 years); tumor characteristics, estrogen receptor (ER)-status, and use of hormone therapy (HT) were included in multivariable models. Results: Compared with hysterectomy alone, premenopausal (< 45 years) BSO at benign hysterectomy was associated with an age and calendar period adjusted HR of 1.48 (95% CI 0.83–2.65) for breast cancer recurrence within 10 years of follow-up, a HR of 1.07 (95% CI 0.66–1.72) for overall mortality after breast cancer, and a HR of 0.59 (95% CI 0.26–1.32) for breast cancer-specific mortality. The corresponding HRs for postmenopausal (≥ 55 years) BSO at benign hysterectomy were 1.51 (95% CI 0.73–3.12) for recurrences, 1.34 (95% CI 0.74–2.44) for overall mortality, and 1.78 (95% CI 0.74–4.30) for breast cancer mortality. Adjusting for tumor characteristics, ER-status and HT did not alter the results. Conclusion: Results from this cohort study did not indicate an improvement in breast cancer prognosis when removing the ovaries at benign hysterectomy prior to the cancer diagnosis.

OriginalsprogEngelsk
TidsskriftBreast Cancer Research and Treatment
Vol/bind197
Udgave nummer3
Sider (fra-til)583-591
Antal sider9
ISSN0167-6806
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The authors would also like to express their gratitude to the Danish Clinical Quality Program (National Clinical Registries (RKKP)) and to the Danish Breast Cancer Group (DBCG). This study was supported by The Mermaid Project, the Danish Cancer Society’s Scientific Committee (KBVU) and Lilly and Herbert Hansen’s Foundation.

Funding Information:
This work was supported by The Mermaid Project (Mermaid 3), the Danish Cancer Society’s Scientific Committee (KBVU) (Grant No. R167-A11019-17-S2) and Lilly and Herbert Hansen’s Foundation (Jr.no. 0145).

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

ID: 340553795